Walls G M, Mitchell J D, Lyon A R, Harbinson M, Hanna G G
Cancer Centre Belfast City Hospital, Belfast Health & Social Care Trust, Lisburn Road, Belfast, Ireland; Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Jubilee Road, Belfast, Ireland.
Cardio-Oncology Center of Excellence, Washington University in St Louis, St Louis, Missouri, USA.
Clin Oncol (R Coll Radiol). 2024 Dec;36(12):745-756. doi: 10.1016/j.clon.2024.09.001. Epub 2024 Sep 10.
Symptomatic radiation cardiotoxicity affects up to 30% patients with lung cancer and several heart substructure doses are associated with reduced overall survival. A greater focus on minimising cardiotoxicity is now possible due to advancements in radiotherapy technology and the new discipline of cardio-oncology, but uptake of emerging data has not been ascertained. A global cross-sectional analysis of Radiation Oncologists who treat lung cancer was therefore conducted by the International Cardio-Oncology Society in order to establish the impact of recently published literature and guidelines on practice.
A bespoke questionnaire was designed following an extensive review of the literature and from recurring relevant themes presented at Radiation Oncology and Cardio-Oncology research meetings. Six question domains were retained following consensus discussions among the investigators, comprising 55 multiple choice stems: guidelines, cardiovascular assessment, cardiology investigations, radiotherapy planning strategies, primary prevention prescribing and local cardio-oncology service access. An invitation was sent to all Radiation Oncologists registered with ICOS and to Radiation Oncology colleagues of the investigators.
In total 118 participants were recruited and 92% were consultant physicians. The ICOS 2021 expert consensus statement was rated as the most useful position paper, followed by the joint ESC-ESTRO 2022 guideline. The majority (80%) of participants indicated that a detailed cardiovascular history was advisable. Although 69% of respondents deemed the availability of cardiac substructure auto-segmentation to be very/quite important, it was implemented by only a few, with the most common being the left anterior descending coronary artery V15. A distinct cardio-oncology service was available to 39% participants, while the remainder utilised general cardiology services.
The uptake of recent guidelines on cardiovascular optimisation is good, but access to cardiology investigations and consultations, and auto-segmentation, represent barriers to modifying radiotherapy practices in lung cancer to reduce the risk of radiation cardiotoxicity.
有症状的放射性心脏毒性影响高达30%的肺癌患者,多个心脏亚结构剂量与总生存期降低相关。由于放射治疗技术的进步和心脏肿瘤学这一新学科的发展,现在有可能更加注重将心脏毒性降至最低,但新兴数据的应用情况尚未确定。因此,国际心脏肿瘤学会对治疗肺癌的放射肿瘤学家进行了一项全球横断面分析,以确定最近发表的文献和指南对实践的影响。
在广泛查阅文献以及参考放射肿瘤学和心脏肿瘤学研究会议上反复出现的相关主题后,设计了一份定制问卷。经过研究者之间的共识讨论,保留了六个问题领域,包括55个多项选择题干:指南、心血管评估、心脏检查、放射治疗计划策略、一级预防处方和当地心脏肿瘤学服务获取情况。向所有在国际心脏肿瘤学会注册的放射肿瘤学家以及研究者的放射肿瘤学同事发出了邀请。
共招募了118名参与者,92%为顾问医师。国际心脏肿瘤学会2021年专家共识声明被评为最有用的立场文件,其次是欧洲心脏病学会-欧洲放射肿瘤学会2022年联合指南。大多数(80%)参与者表示,详细的心血管病史是可取的。尽管69%的受访者认为心脏亚结构自动分割的可用性非常/相当重要,但只有少数人实施了,最常见的是左前降支冠状动脉V15。39%的参与者可以获得专门的心脏肿瘤学服务,其余的则利用普通心脏病学服务。
近期心血管优化指南的应用情况良好,但心脏检查和会诊以及自动分割的获取是改变肺癌放疗实践以降低放射性心脏毒性风险的障碍。